Engineered donor T cells after stem cell transplant for blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests specially engineered donor T cells (TSC-100 or TSC-101) given after a stem cell transplant to help prevent cancer relapse in people with AML, MDS, or ALL. It is for patients who have a specific genetic marker (HA-1 or HA-2) and a matched donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have AML, MDS, or ALL
- You are planning to have a stem cell transplant from a haploidentical, mismatched unrelated, or matched unrelated donor
- You have the HA-1 or HA-2 genetic marker (this will be tested)
- You have the HLA-A*0201 type (this will be tested)
- You have an ECOG performance status of 0 to 2 (can do daily activities with little or no help)
- You agree to follow birth control rules and long-term follow-up for up to 15 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (BSB-1001) given after a stem cell transplant to prevent or treat high-risk blood cancers like AML, ALL, or MDS. It is for patients with a specific genetic marker and a matched donor.
This trial tests whether giving specially engineered donor T-cells after a stem cell transplant can help treat certain blood cancers like AML or MDS. The study is for people receiving a donor stem cell transplant for the first time.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.